The joint statement by Indiana University Health, Community Health Network and Eskenazi Health is the latest pledge by Indianapolis-area business groups to address racial inequities.
What leads to a strong and sustainable business? We’d like to suggest three aspects leaders need to pay attention to: values, relationships and balance.
A panel of experts spoke at IBJ’s Life Sciences Power Breakfast, which took place virtually Oct. 9, talked about venture capital in the life sciences sector. These are some excerpts.
We urge more companies to make similar commitments, whether they do so publicly by participating in the equity pledge or privately with accountability from within their own organizations.
The Indy Racial Equity Pledge, launched Oct. 8, details what nine Indianapolis-area employers plan to do to improve racial equity within their organizations, the Indianapolis area, and beyond.
Eli Lilly and Co. on Thursday announced that it has agreed to acquire Disarm Therapeutics, a private biotechnology company that is developing therapies that could be used to treat multiple sclerosis, glaucoma, Alzheimer’s disease and ALS.
Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.
Indianapolis-based Eli Lilly and Co. said it made the decision on recommendation of the Data and Safety Monitoring Board “out of an abundance of caution.”
Eli Lilly and Co. already has begun manufacturing the drug and expects to have 1 million doses by December, the executive in charge of COVID-19 research said Friday at IBJ’s Life Sciences Power Breakfast.
Experimental antibody drugs like the one President Trump was given and the one Eli Lilly is developing are among the most promising therapies being tested for treating and preventing coronavirus infections. Here’s how they work.
The pledge “to hold their organizations accountable for driving measurable progress in advancing racial equity” was signed by numerous major employers and organizations in central Indiana.
Seemingly sensitive to the fact that his treatment course has been far more comprehensive than the care received by average Americans, he promised to swiftly get the drug approved for broader use.
Shares of Lilly jumped 3.7%, or $5.41, to $149.54 in afternoon trading following the company’s morning announcement that it has asked the U.S. government to allow emergency use of the therapy to treat the disease.
Eli Lilly and Co. says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on positive early results from a study.
Bart Peterson, former two-term mayor of Indianapolis, said he returned to the educational not-for-profit to fill a gap left by the death of Christel DeHaan in June.
A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
It’s a big pivot for organizations that traditionally create high-visibility fall projects to call attention to volunteerism and community service. In the process, they help dozens of neighborhood groups and scores of not-for-profits, from the United Way of Central Indiana to Keep Indianapolis Beautiful.
For Indy’s employers—large and small—to remain strong, they need a working environment in which the most innovative ideas and strongest strategies emerge, and we believe for most firms, that’s tough to accomplish in a remote work environment.
A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients.
